Published online February 4, 2008
PEDIATRICS Vol. 121 No. 3 March 2008, pp. e714-e717 (doi:10.1542/10.1542/peds.2007-0665)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, K. H.
Right arrow Articles by Burton, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, K. H.
Right arrow Articles by Burton, B. K.
Related Collections
Right arrow Genetics & Dysmorphology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

EXPERIENCE & REASON

Successful Management of Difficult Infusion-Associated Reactions in a Young Patient With Mucopolysaccharidosis Type VI Receiving Recombinant Human Arylsulfatase B (Galsulfase [Naglazyme])

Katherine H. Kim, MSa,b, Celeste Decker, MDc and Barbara K. Burton, MDa,b

a Division of Genetics, Birth Defects, and Metabolism, Children's Memorial Hospital, Chicago, Illinois
b Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
c BioMarin Pharmaceutical Inc, Novato, California

ABSTRACT

Our patient with mucopolysaccharidosis type VI received enzyme replacement therapy with recombinant human arylsulfatase B (galsulfase [Naglazyme, BioMarin Pharmaceutical Inc, Novato, CA]) shortly after approval by the US Food and Drug Administration. After 1 month of weekly infusions, the patient developed significant infusion-associated reactions and could not tolerate therapy at the recommended infusion rate. We were able to continue treatment successfully by the addition of steroids to the premedication regimen and by significantly reducing the rate of drug infusion. Over the next several months, the patient's infusion rate was slowly increased and the premedications were weaned. We demonstrate that by significantly reducing the rate of infusions and adjusting the premedication regimen, galsulfase infusions can continue with no additional observance of infusion-associated reactions.

Key Words: MPS VI • management • enzyme replacement therapy • recombinant human arylsulfatase B • galsulfase • Naglazyme

Abbreviations: MPS VI, mucopolysaccharidosis type VI • ASB, arylsulfatase B • GAG, glycosaminoglycan • ERT, enzyme replacement therapy • IAR, infusion-associated reactions

Accepted Jul 27, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?